Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pivalate SCHEMBL28522169 | 0.87 | ALDH1A1 (0.44) | ALDH1A1TSHRLMNACYP2C19CYP2D6 | |
| Pivalate SCHEMBL28490918 | 0.87 | ALDH1A1 (0.44) | ALDH1A1TSHRLMNACYP2C19CYP2D6 | |
| Pivalate SCHEMBL27990395 | 0.87 | ALDH1A1 (0.44) | ALDH1A1TSHRLMNACYP2C19CYP2D6 | |
| Pivalate SCHEMBL10718027 | 0.84 | LMNA (0.62) | ALDH1A1TSHRLMNACYP2C19CYP2D6 | |
| Pivalate SCHEMBL28069023 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP2C19CYP2D6HIF1A | |
| Pivalate SCHEMBL27519097 | 0.82 | — | — | |
| Pivalate SCHEMBL4318862 | 0.82 | — | — | |
| Pivalate SCHEMBL5116637 | 0.82 | TSHR (0.61) | ALDH1A1TSHRLMNACYP2C19CYP2D6 | |
| Pivalate SCHEMBL332912 | 0.82 | TSHR (0.61) | ALDH1A1TSHRLMNACYP2C19CYP2D6 | |
| Pivalate SCHEMBL3613 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852852-B2 | Method of producing regioselectively substituted esters of oligo- and polysaccharides | WOLFF WALSRODE AG (DE) | 2005-02-08 | — | — | US | disclosed |
| US-20030162745-A1 | Method of producing regioselectively substituted esters of oligo- and polysaccharides | DOW GLOBAL TECHNOLOGIES INC. | 2003-08-28 | — | — | US | disclosed |
| US-6489468-B1 | REGIOSELECTIVELY SUBSTITUTED, PREDOMINANTLY AT THE C2 POSITION OF THE ANHYDROGLUCOSE UNIT (AGU); STARCH ESTERS | WOLFF WALSRODE AG (DE) | 2002-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162745-A1 | Method of producing regioselectively substituted esters of oligo- and polysaccharides | OSTC, SI, OGT | ALDH1A1 3321/4885TSHR 3093/4885LMNA 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.